In this section

The Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context

McMurray, J. J.V. , Solomon, S. D., Docherty, K. F. and Jhund, P. S. (2021) The Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. European Heart Journal, 42(13), pp. 1199-1202. (doi: 10.1093/eurheartj/ehz916) (PMID:31898736) (PMCID:PMC8014512)

[img] Text
207585.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.
298kB

Abstract

No abstract available.

Item Type:Articles
Additional Information:The DAPA-HF trial was funded by AstraZeneca.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Docherty, Dr Kieran and Jhund, Professor Pardeep and McMurray, Professor John
Authors: McMurray, J. J.V., Solomon, S. D., Docherty, K. F., and Jhund, P. S.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:European Heart Journal
Publisher:Oxford University Press
ISSN:0195-668X
ISSN (Online):1522-9645
Published Online:03 January 2020
Copyright Holders:Copyright © 2020 The Authors
First Published:First published in European Heart Journal 42(13): 1199-1202
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Deposit and Record Details